Clinical study on the cancer immunotherapy approved for phase 1


A cancer immunotherapy research group at Baylor College of Medicine has secured the liquidation of new drug investigations through the FDA to carry out phase I clinical trials in adult patients with glioblastoma (GBM), a highly lethal form of Brain cancer with a five-year survival rate of less than 10% in most age groups.

The regulatory goal is the second for Dr. William DeckerThe Baylor academic immunotherapy group for cancer has also received FDA authorization to conduct resuscitative pancreatic cancer immunotherapy studies in July 2018.

Pending institutional approval, the glioblastoma study will be conducted at Cooper's MD Anderson Cancer Center in Camden, NJ, and overseen by Dr. Joseph Georges, a resident neurosurgeon at Cooper University Health Care and the Philadelphia College of Osteopathic Medicine. "I saw the power of this vaccination approach in the laboratory during my doctoral studies, and I believe it has the potential to help our patients with glioblastoma," Georges said.

The vaccine technology developed by Decker's laboratory works by "tricking" the immune system into the treatment of cancer as it would be a viral infection by reprogramming powerful immune cells known as dendritic cells.

"If you can convince the immune system that the cancer is a viral infection," said Decker, associate professor of pathology and immunology at Baylor, "you can generate a more powerful anticancer immune response than would normally be possible with normal techniques. of vaccination ". Decker is also a member of the Center for Overall Cancer Dan L Duncan of Baylor.

"We are very excited to take part in this initiative. New and innovative treatments like this are desperately needed to improve the negative outcomes of this devastating disease," said Dr. Nati Lerman, medical oncologist at MD Anderson at Cooper and contributor to the vaccine trial.

The marketing rights of the enabling technologies developed by Baylor have been granted by the Baylor Licensing Group to Diakonos Research, Ltd.

"We are extremely proud of the incredible work done by our scientific and clinical partners at Baylor College of Medicine and MD Anderson at Cooper in New Jersey," said Dan Faust, CEO of Diakonos Research. "When Dr. Decker and his team demonstrate the same favorable safety profile in human studies that has already been demonstrated in mice and dogs, Diakonos is ready to provide valuable resources for randomized, double-blind controlled trials with placebos that will bring this technology to the market. For us it's about patients. We want to save as many lives as possible. "

Research of Diakonos, a Houston-based limited liability company, was founded in 2015 with the mission to commercialize life-saving technologies developed by researchers at the Texas Medical Center.

Financial support for the clinical study is provided by a charitable cancer foundation.

/ Public release. View in full Here.

. (tagToTranslate) Baylor College of Medicine (t) Camden (t) Texas (t) Anderson (t) New Jersey (t) immunotherapy (t) vaccination (t) university (t) professor (t) infection (t) resources (t ) medicine (t) research (t) of disease (t) the vaccine


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.